BR9913222A - Aza-biciclos que modulam a inibição de adesão das células - Google Patents
Aza-biciclos que modulam a inibição de adesão das célulasInfo
- Publication number
- BR9913222A BR9913222A BR9913222-2A BR9913222A BR9913222A BR 9913222 A BR9913222 A BR 9913222A BR 9913222 A BR9913222 A BR 9913222A BR 9913222 A BR9913222 A BR 9913222A
- Authority
- BR
- Brazil
- Prior art keywords
- bond
- acidic
- alkyl
- alkylene
- aza
- Prior art date
Links
- 230000021164 cell adhesion Effects 0.000 title abstract 2
- 230000005764 inhibitory process Effects 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 230000002378 acidificating effect Effects 0.000 abstract 3
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 125000000524 functional group Chemical group 0.000 abstract 2
- -1 imino, oxo, thioxo Chemical group 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 239000000651 prodrug Substances 0.000 abstract 2
- 102000016359 Fibronectins Human genes 0.000 abstract 1
- 108010067306 Fibronectins Proteins 0.000 abstract 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 abstract 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 abstract 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000005724 cycloalkenylene group Chemical group 0.000 abstract 1
- 125000002993 cycloalkylene group Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
- C07D215/08—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Patente de Invenção: <B>"AZA-BICICLOS QUE MODULAM A INIBIçãO DE ADESãO DAS CéLULAS"<D>. A invenção é dirigida aos compostos fisiologicamente ativos de fórmula (I), na qual R¹ representa R³-Z³-, R³-L²-R^ 4^-Z³-, R³-L³-Ar¹-L^ 4^-Z³- ou R³-L³-Ar¹-L²-R^ 4^-Z³-; R² representa hidrogênio, halogênio, alquila inferior ou alcóxi inferior; A¹ representa uma ligação de C~ 1-3~ alquileno de cadeia reta, opcionalmente substituída por um ou mais grupos escolhidos de alquila, arila, arilalquila, heteroarila, heteroarilalquila, imino, oxo, tioxo, ou alquila substituída por -ZR^ 6^, -NY¹Y², -CO~ 2~R^ 6^ ou -C(=O)-NY¹Y²; L¹ representa uma ligação direta; uma ligação alquenileno, alquileno, alquinileno, cicloalquenileno, cicloalquileno, heteroarildiíla, heterocicloalquileno ou arileno, cada uma opcionalmente substituída por (a) um grupo funcional acídico, ciano, oxo, -S(O)~ m~R^ 9^, R³, -C(=O)-R³, -C(=O)-OR³, -N(R^ 8^)-C(=O)-R^ 9^, -N(R^ 8^)-C(=O)-OR^ 9^, -N(R^ 8^)-SO~ 2~-R^ 9^, -NY^ 4^Y^ 5^ ou -[C(=O)-N(R^ 10^)-C(R^ 5^)(R^ 11^)]~ p~-C(=O)-NY^ 4^Y^ 5^, ou por (b) alquila substituída por um grupo funcional acídico, ou por S(O)~ m~R^ 9^, -C(=O)-NY^ 4^Y^ 5^ ou -NY^ 4^Y^ 5^; uma ligação -[C(=O)-N(R^ 10^)-C(R^ 5^)(R^ 11^)]~ p~-; uma ligação -Z²-R^ 12^-; uma ligação -C(=O)-CH~ 2~-C(=O)-; uma ligação -R^ 12^-Z²-R^ 12^-; uma ligação -C(R^ 4^)(R^ 13^)-[C(=O)-N(R^ 10^)-C(R^ 5^)(R^ 11^)]~ p~; ou uma ligação -L^ 5^-L^ 6^-L^ 7^-; Z¹ é C(R^ 7^)(R^ 7a^), C(=O) ou CH(OH); Y é carbóxi ou um bioisóstero ácido; e os N-óxidos correspondentes, e seus pró-medicamentos; e os sais farmaceuticamente aceitáveis e os solvatos de tais compostos e de seus N-óxidos e pró-medicamentos. Tais compostos têm propriedades farmacêuticas valiosas, em particular a capacidade de regular a interação da VCAM-1 e da fibronectina com a integridina VLA-4 (<<244>4<225>1).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9818641.4A GB9818641D0 (en) | 1998-08-26 | 1998-08-26 | Chemical compounds |
US11000898P | 1998-11-25 | 1998-11-25 | |
PCT/GB1999/002819 WO2000015612A1 (en) | 1998-08-26 | 1999-08-26 | Aza-bicycles which modulate the inhibition of cell adhesion |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9913222A true BR9913222A (pt) | 2001-10-16 |
Family
ID=26314269
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9913222-2A BR9913222A (pt) | 1998-08-26 | 1999-08-26 | Aza-biciclos que modulam a inibição de adesão das células |
Country Status (21)
Country | Link |
---|---|
US (1) | US6608084B1 (pt) |
EP (1) | EP1114028B1 (pt) |
KR (1) | KR20010085630A (pt) |
CN (1) | CN1323295A (pt) |
AT (1) | ATE346841T1 (pt) |
AU (1) | AU754557B2 (pt) |
BR (1) | BR9913222A (pt) |
CA (1) | CA2341677A1 (pt) |
DE (1) | DE69934238T2 (pt) |
DK (1) | DK1114028T3 (pt) |
ES (1) | ES2276530T3 (pt) |
HU (1) | HUP0104766A3 (pt) |
IL (2) | IL141596A0 (pt) |
MX (1) | MXPA01001995A (pt) |
NO (1) | NO20010942L (pt) |
NZ (1) | NZ509781A (pt) |
PL (1) | PL346248A1 (pt) |
PT (1) | PT1114028E (pt) |
SK (1) | SK2612001A3 (pt) |
TR (1) | TR200100588T2 (pt) |
WO (1) | WO2000015612A1 (pt) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2370805C (en) | 1999-05-05 | 2012-07-03 | Aventis Pharma Limited | Ureas as cell adhesion modulators |
AP2002002565A0 (en) | 1999-12-28 | 2002-06-30 | Pfizer Prod Inc | Non-peptidyl inhibitors of VLA-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases. |
AU2001235806A1 (en) * | 2000-03-01 | 2001-09-12 | Aventis Pharma Limited | 2,3-dihydro-1h-indolinyl-alkanoic acids as cell adhesion inhibitors |
AU2001256733A1 (en) * | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
FR2812633A1 (fr) * | 2000-08-04 | 2002-02-08 | Aventis Cropscience Sa | Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides |
MXPA03003829A (es) * | 2000-11-04 | 2003-07-28 | Aventis Pharma Ltd | Acidos alcanoicos substituidos. |
CN100471838C (zh) | 2000-12-28 | 2009-03-25 | 第一制药株式会社 | Vla-4抑制剂 |
PT1392306E (pt) * | 2001-06-06 | 2008-03-07 | Aventis Pharma Ltd | Tetra-hidroisoquinolinas substituídas para utilização no tratamento de doenças inflamatórias |
US7557130B2 (en) | 2001-07-26 | 2009-07-07 | Ucb Pharma, S.A. | Bicyclic heteroaromatic alanines |
AU2003232472B2 (en) | 2002-04-30 | 2008-09-18 | Ucb Pharma | 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them and their uses as VLA-4 inhibitors |
BRPI0408248A (pt) | 2003-03-12 | 2006-03-01 | Pfizer Prod Inc | derivados azabicìclicos de piridiloximetila e de benzisoxazol |
TWI340134B (en) | 2003-07-24 | 2011-04-11 | Daiichi Seiyaku Co | Cyclohexanecarboxylic acids |
NZ563739A (en) | 2005-06-09 | 2009-12-24 | Ucb Pharma Sa | 2,6 Quinolinyl derivatives, processes for preparing them and their use as medicament |
US7741317B2 (en) * | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
US7790745B2 (en) * | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
CN101360736A (zh) * | 2005-11-23 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | L-丙氨酸衍生物 |
WO2007141473A1 (en) * | 2006-06-09 | 2007-12-13 | Astrazeneca Ab | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl] -l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
WO2008093065A1 (en) * | 2007-01-29 | 2008-08-07 | Astrazeneca Ab | L-ALANINE DERIVATIVES AS α5βL ANTAGONISTS |
WO2008125811A1 (en) * | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
UY32470A (es) * | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
CA2766033C (en) * | 2009-06-25 | 2016-09-20 | Alkermes, Inc. | Prodrugs of nh-acidic compounds |
WO2010151689A1 (en) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Heterocyclic compounds for the treatment of neurological and psychological disorders |
US20110166194A1 (en) * | 2010-01-07 | 2011-07-07 | Alkermes, Inc. | Asenapine Prodrugs |
WO2011084850A1 (en) * | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Prodrugs for the treatment of schizophrenia and bipolar disease |
JP6076740B2 (ja) * | 2010-01-07 | 2017-02-08 | アルカーメス ファーマ アイルランド リミテッド | 第四級アンモニウム塩プロドラッグ |
WO2011084849A1 (en) * | 2010-01-07 | 2011-07-14 | Alkermes, Inc. | Diaryldiazepine prodrugs for the treatment of neurological and psychological disorders |
EP2521545B1 (en) | 2010-01-07 | 2019-11-27 | Alkermes Pharma Ireland Limited | Prodrugs of heteroaromatic compounds |
US8598156B2 (en) | 2010-03-25 | 2013-12-03 | Glaxosmithkline Llc | Chemical compounds |
AU2011270701B2 (en) | 2010-06-24 | 2015-05-14 | Alkermes Pharma Ireland Limited | Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US8586604B2 (en) | 2010-08-20 | 2013-11-19 | Boehringer Ingelheim International Gmbh | Inhibitors of the microsomal prostaglandin E2 synthase-1 |
US8759537B2 (en) | 2010-08-20 | 2014-06-24 | Boehringer Ingelheim International Gmbh | 3H-imidazo [4, 5-C] pyridine-6-carboxamides as anti-inflammatory agents |
US8674113B2 (en) | 2010-12-10 | 2014-03-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8466186B2 (en) | 2010-12-10 | 2013-06-18 | Boehringer Ingelheim International Gmbh | Compounds |
US8486968B2 (en) | 2010-12-10 | 2013-07-16 | Boehringer Ingelheim International Gmbh | Compounds |
US8894846B2 (en) * | 2010-12-23 | 2014-11-25 | Stephen Lee Yarbro | Using supercritical fluids to refine hydrocarbons |
SI3156056T1 (sl) | 2011-03-18 | 2024-03-29 | Alkermes Pharma Ireland Limited | Farmacevtski sestavki, ki obsegajo estre sorbitana |
GB201106817D0 (en) | 2011-04-21 | 2011-06-01 | Astex Therapeutics Ltd | New compound |
EP2790734B1 (en) | 2011-12-15 | 2019-02-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
NZ630643A (en) | 2012-03-19 | 2017-08-25 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions comprising fatty acid esters |
WO2013142202A1 (en) | 2012-03-19 | 2013-09-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising glycerol esters |
JP6333802B2 (ja) | 2012-03-19 | 2018-05-30 | アルカームス ファーマ アイルランド リミテッド | ベンジルアルコールを含む医薬組成物 |
CA2885196C (en) | 2012-09-19 | 2021-06-22 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
GB201218864D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
US9980973B2 (en) | 2012-10-19 | 2018-05-29 | Astex Therapeutics Limited | Bicyclic heterocycle compounds and their uses in therapy |
GB201218862D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
GB201218850D0 (en) | 2012-10-19 | 2012-12-05 | Astex Therapeutics Ltd | Bicyclic heterocycle compounds and their uses in therapy |
JP6470756B2 (ja) | 2013-12-20 | 2019-02-13 | アステックス、セラピューティックス、リミテッドAstex Therapeutics Limited | 二環式複素環化合物および治療におけるそれらの使用 |
RU2688233C2 (ru) | 2014-03-20 | 2019-05-21 | Алкермес Фарма Айэленд Лимитед | Препараты арипипразола, имеющие повышенные скорости впрыска |
CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
JP7214882B2 (ja) | 2018-10-30 | 2023-01-30 | ギリアード サイエンシーズ, インコーポレイテッド | アルファ4ベータ7インテグリン阻害剤としてのイミダゾピリジン誘導体 |
CN112969687A (zh) | 2018-10-30 | 2021-06-15 | 吉利德科学公司 | 作为α4β7整合素抑制剂的喹啉衍生物 |
AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
KR20220047323A (ko) | 2019-08-14 | 2022-04-15 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1497118A1 (de) * | 1965-05-29 | 1969-04-17 | Agfa Gevaert Ag | Sensibilisierte elektrophotographische Schichten |
ES503097A0 (es) | 1980-06-18 | 1982-10-01 | May & Baker Ltd | Procedimiento para preparar derivados de indol o de indolina |
DE68920147T2 (de) * | 1989-10-12 | 1995-06-29 | Ibm | Anzeigesystem. |
WO1995015973A1 (en) * | 1993-12-06 | 1995-06-15 | Cytel Corporation | Cs-1 peptidomimetics, compositions and methods of using the same |
AU4080597A (en) * | 1996-08-23 | 1998-03-06 | Board Of Regents For Oklahoma State University, The | Heteroarotinoids-anticancer agents with receptor specificity and tgase activity |
DE19647381A1 (de) * | 1996-11-15 | 1998-05-20 | Hoechst Ag | Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten |
-
1999
- 1999-08-26 CN CN99811991A patent/CN1323295A/zh active Pending
- 1999-08-26 NZ NZ509781A patent/NZ509781A/en unknown
- 1999-08-26 PT PT99943058T patent/PT1114028E/pt unknown
- 1999-08-26 TR TR2001/00588T patent/TR200100588T2/xx unknown
- 1999-08-26 PL PL99346248A patent/PL346248A1/xx not_active Application Discontinuation
- 1999-08-26 EP EP99943058A patent/EP1114028B1/en not_active Expired - Lifetime
- 1999-08-26 WO PCT/GB1999/002819 patent/WO2000015612A1/en active IP Right Grant
- 1999-08-26 SK SK261-2001A patent/SK2612001A3/sk unknown
- 1999-08-26 MX MXPA01001995A patent/MXPA01001995A/es not_active IP Right Cessation
- 1999-08-26 DK DK99943058T patent/DK1114028T3/da active
- 1999-08-26 DE DE69934238T patent/DE69934238T2/de not_active Expired - Lifetime
- 1999-08-26 US US09/856,106 patent/US6608084B1/en not_active Expired - Lifetime
- 1999-08-26 AT AT99943058T patent/ATE346841T1/de not_active IP Right Cessation
- 1999-08-26 ES ES99943058T patent/ES2276530T3/es not_active Expired - Lifetime
- 1999-08-26 BR BR9913222-2A patent/BR9913222A/pt not_active Application Discontinuation
- 1999-08-26 AU AU56343/99A patent/AU754557B2/en not_active Ceased
- 1999-08-26 KR KR1020017002476A patent/KR20010085630A/ko not_active Application Discontinuation
- 1999-08-26 IL IL14159699A patent/IL141596A0/xx active IP Right Grant
- 1999-08-26 CA CA002341677A patent/CA2341677A1/en not_active Abandoned
- 1999-08-26 HU HU0104766A patent/HUP0104766A3/hu unknown
-
2001
- 2001-02-22 IL IL141596A patent/IL141596A/en not_active IP Right Cessation
- 2001-02-23 NO NO20010942A patent/NO20010942L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NO20010942D0 (no) | 2001-02-23 |
HUP0104766A2 (hu) | 2002-04-29 |
SK2612001A3 (en) | 2001-11-06 |
ATE346841T1 (de) | 2006-12-15 |
CN1323295A (zh) | 2001-11-21 |
NO20010942L (no) | 2001-04-19 |
NZ509781A (en) | 2003-05-30 |
CA2341677A1 (en) | 2000-03-23 |
EP1114028B1 (en) | 2006-11-29 |
EP1114028A1 (en) | 2001-07-11 |
MXPA01001995A (es) | 2004-07-30 |
DE69934238T2 (de) | 2007-06-21 |
KR20010085630A (ko) | 2001-09-07 |
PT1114028E (pt) | 2007-02-28 |
AU754557B2 (en) | 2002-11-21 |
DK1114028T3 (da) | 2007-04-30 |
DE69934238D1 (de) | 2007-01-11 |
TR200100588T2 (tr) | 2001-08-21 |
WO2000015612A1 (en) | 2000-03-23 |
AU5634399A (en) | 2000-04-03 |
ES2276530T3 (es) | 2007-06-16 |
PL346248A1 (en) | 2002-01-28 |
US6608084B1 (en) | 2003-08-19 |
IL141596A0 (en) | 2002-03-10 |
IL141596A (en) | 2006-07-05 |
HUP0104766A3 (en) | 2002-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9913222A (pt) | Aza-biciclos que modulam a inibição de adesão das células | |
IS6257A (is) | Frumuviðloðunartálmar | |
BR9807339A (pt) | Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos. | |
BR9913592A (pt) | Compostos, processo de preparação dos compostos, e, composições farmacêuticas | |
MXPA01010231A (es) | Compuestos heteroarilo biciclicos sustituidos como antagonistas de integrina. | |
IT1295694B1 (it) | Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica | |
BR9813360A (pt) | Derivados de ácido hidroxâmico como inibidores de metaloprotease de matriz (mmp) | |
ID27757A (id) | Indolinona-indolinona tersubstitusi baru, preparasi dan penggunaannya sebagai obat | |
EA200500091A1 (ru) | Фосфатные соли карведилола и/или их сольваты, соответствующие композиции и/или способы лечения | |
DK1153017T3 (da) | Bicykliske forbindelser og deres anvendelse som integrinreceptorligander | |
AR044400A1 (es) | Procesos para la preparacion de derivados de pirimidina | |
BR0210285A (pt) | Utilização de um composto, composto e composição farmacêutica | |
NO934196L (no) | N,N-disubstituerte arylcykloalkylaminer, deres salter, legemidler inneholdende disse forbindelser, deres anvendelse og fremgangsmåte for deres fremstilling | |
BR0211334A (pt) | Processo de sìntese de derivados do ácido (2s, 3as, 7as)-1-[(s)alanil]-octahidro-lh-indol-2-carboxìlico e aplicação a sìntese do perindopril | |
BRPI0813809A2 (pt) | derivados de 7-alquinil -1,8-naftiridonas, sua preparação e sua aplicação em terapêutica. | |
BR9814376A (pt) | Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &4ß1, e, resina | |
NO20020029D0 (no) | Fremgangsmåte for fremstilling av amilodipinbenzensulfonat | |
BR9802544A (pt) | Derivados de hexahidro-1,4-diazepina os seus sais. | |
BR0016921A (pt) | Tetrahidropiridinas, processo para sua preparação e composições farmacêuticas que as contêm | |
BG104786A (en) | Dihydro-benzo(1,4)oxazines and tetrahydroquinoxalines | |
BR0008068A (pt) | Derivados de piperidina e piperazina comoinibidores da formação de fibrilas a-beta | |
BR9805246A (pt) | Derivados de benzotiofeno úteis em terapia. | |
DK0441467T3 (da) | Sidekædehomologe vitamin D-derivater, fremgangsmåde til fremstilling heraf, farmaceutiske præparater indeholdende disse derivater samt deres anvendelse som lægemiddel | |
DK0541263T3 (da) | 5-Piperazinylalkyl-1,5-benzothiazepinoner, der er nyttige som calciumantagonister | |
BR0214973A (pt) | Derivados de benzotiazina e benzotiadiazina, seu processo de preparação e as composições farmacêuticas que os contêm |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |